AbbVie is progressing zuilokibart—an antibody acquired through its Apogee deal—into Phase 3 evaluation for atopic dermatitis, as competitors continue to push long-acting and targeted anti-inflammatory options. The program’s timing comes as multiple companies report incremental clinical readouts across IL-4/IL-13 and related immune pathways, and as investors compare next-generation efficacy, dosing convenience and safety. While details on trial design and endpoints were not fully provided in the excerpt, the Phase 3 step signals AbbVie’s intention to build a late-stage package for potential label expansion in a highly competitive immunology market.